Critique: Makary’s time atop FDA over, Diamantas named acting commissioner

Source: politico
Authors: David Lim, Lauren Gardner
URL: https://www.politico.com/news/2026/05/12/makary-fda-resign-white-house-00916014

## What the article reports
Martin Makary's tenure as FDA Commissioner has ended; Sara Diamantas has been named acting commissioner. The departure was reportedly orchestrated by HHS Secretary Robert F. Kennedy Jr. and attributed to a cluster of political conflicts including abortion-pill policy, vape authorization, and pharmaceutical-industry friction.

## Factual accuracy — Partial
The piece makes several specific claims that are not independently verifiable from the text itself. Makary is correctly identified as a "Johns Hopkins surgeon," a checkable credential. The claim that "HHS Secretary Robert F. Kennedy Jr. made the call" is sourced to a single anonymous official and stands alone — no documentary record, on-record spokesperson statement, or White House statement corroborates it. The assertion that Makary "was pressured by President Donald Trump to authorize flavored vapes after initially raising concern" is a factual claim about presidential conduct that also rests on no named source. The article does not note whether Makary or the FDA press office was asked for comment, which is a basic verification step. For a 207-word wire-style dispatch, the density of unverified specific claims is notable.

## Framing — Mixed
1. **"marked by mass layoffs, persistent churn among senior leaders and policy fights"** — The characterization of the tenure is entirely negative; no countervailing accomplishment (approvals issued, policies enacted) is mentioned. This frames Makary's time at FDA as unambiguously troubled before any sourced voice speaks.
2. **"a confluence of events ultimately led to his departure"** — The authorial-voice construction presents causation as settled ("ultimately led") without attribution, embedding an interpretive conclusion as fact.
3. **"He is a cat so we will see"** — The cat metaphor is the most vivid and memorable line in the piece; it comes from an anonymous official and is placed as the closing note before the final paragraph, giving it unusual narrative weight.
4. The headline names Diamantas but the body contains zero information about her — a mismatch between what the headline implies (a transition story) and what the article actually covers (an exit story).

## Source balance
| Voice | Affiliation | Stance |
|---|---|---|
| Senior administration official (anonymous) | White House/HHS | Critical of Makary / supportive of Kennedy's decision |
| Unnamed official (anonymous) | FDA staff | Ambiguous ("cat" remark) |
| Unnamed FDA staff (collective) | FDA | Neutral (normalcy claim) |

**Ratio:** Two anonymous sources, both framing the departure as internally driven or at least unsurprising. Zero named sources. No voice from Makary, his office, the FDA press shop, Republican lawmakers mentioned, biopharmaceutical companies mentioned, or reproductive-rights advocates mentioned. The sourcing is effectively 2:0 (against Makary : for Makary) with no neutral expert.

## Omissions
1. **Makary's record of accomplishments** — The article lists only controversies; a reader has no basis to weigh the tenure. Any approvals, public-health actions, or positive stakeholder assessments are absent.
2. **Who is Sara Diamantas?** — Named in the headline and nowhere else in the body. Her role, background, and the terms of the acting appointment are entirely unaddressed.
3. **Historical context on FDA commissioner turnover** — How does Makary's stint compare in length and controversy to prior commissioners? That baseline would help readers assess whether this departure is unusual.
4. **Makary's or FDA's on-record response** — Standard news practice is to note whether the departing official commented or declined to comment. No such note appears.
5. **The mifepristone and vape policy details** — Both are mentioned as causes of conflict but neither is explained; a reader unfamiliar with either controversy gets no context for why these were politically consequential.

## What it does well
- The piece moves quickly and efficiently establishes the central news fact — Makary is out, Diamantas is in — in a short format appropriate for a breaking bulletin.
- "leadership was working this week as if nothing was amiss" is a concrete, scene-setting detail that conveys the abruptness of the departure without editorializing.
- Attributing Kennedy's specific role — "It was really Secretary Kennedy himself who made this decision" — gives the sourcing at least a direct quote, even if anonymous, rather than a paraphrase.
- The three-part list of political conflicts (abortion pill, vapes, pharmaceutical reviews) provides structural clarity about the disputes involved, even without elaboration.

## Rating
| Dimension | Score | One-line justification |
|---|---|---|
| Factual accuracy | 6 | Key causal and attributional claims rest on a single anonymous source with no corroboration noted |
| Source diversity | 3 | Two anonymous officials, both framing events unfavorably to Makary; no named sources, no opposing voices |
| Editorial neutrality | 6 | Authorial framing ("mass layoffs," "ultimately led") presents contested interpretations as settled; no balancing characterization of tenure |
| Comprehensiveness/context | 4 | Diamantas unexplained, Makary's record one-sided, no historical FDA comparison, policy conflicts unexplained |
| Transparency | 6 | No byline note on whether FDA was contacted; anonymity grants stated but not justified beyond "to speak candidly" |

**Overall: 5/10 — A fast-moving bulletin that prioritizes a single-source narrative over the sourcing rigor and contextual depth the story's significance warrants.**